Leerink Partners Raises Twist Bioscience (NASDAQ:TWST) Price Target to $48.00

Twist Bioscience (NASDAQ:TWST) had its price target lifted by Leerink Partners from $45.00 to $48.00 in a research note published on Thursday morning, Benzinga reports. The firm currently has a market perform rating on the stock.

Other analysts have also issued research reports about the company. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. Barclays dropped their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Finally, Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Stock Up 3.1 %

Shares of NASDAQ TWST opened at $46.93 on Thursday. The stock’s fifty day simple moving average is $43.98 and its 200 day simple moving average is $44.30. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -13.97 and a beta of 1.77. Twist Bioscience has a 52-week low of $14.42 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. During the same quarter in the previous year, the firm posted ($1.01) EPS. Twist Bioscience’s quarterly revenue was up 27.7% on a year-over-year basis. As a group, analysts anticipate that Twist Bioscience will post -3.13 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 5,139 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $205,200.27. Following the transaction, the chief executive officer now owns 499,593 shares in the company, valued at $19,948,748.49. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now owns 495,523 shares in the company, valued at $23,259,849.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Emily M. Leproust sold 5,139 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the completion of the sale, the chief executive officer now owns 499,593 shares of the company’s stock, valued at $19,948,748.49. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,246 shares of company stock valued at $1,829,356. 3.92% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TWST. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the second quarter valued at about $43,000. Blue Trust Inc. grew its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the 2nd quarter valued at approximately $61,000. Nisa Investment Advisors LLC increased its position in Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares during the period. Finally, CWM LLC lifted its holdings in shares of Twist Bioscience by 27.4% during the second quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.